Project 7

Project 7

Goal & Research Areas

Oral small molecule inhibitors of NSP4-mediated membrane-associated RNA replication of SARS-CoV-2 and other RNA viruses

Core Leader & Team

Jeffrey Glenn

Jeffrey Glenn

Learn More Learn More
Mark Smith

Mark Smith

Learn More Learn More
Nam-Joon Cho

Nam-Joon Cho

Learn More Learn More
Wah Chiu

Wah Chiu

Learn More Learn More
Phil Santangelo

Chien-Te (Kent) Tsen

Learn More Learn More

Hot Topic

Jeffrey Glenn receives $69 million to start antiviral drug-discovery center at Stanford

Jeffrey Glenn receives $69 million to start antiviral drug-discovery center at Stanford

The National Institute for Allergy and Infectious Diseases has awarded Jeffrey Glenn, MD, PhD, professor of hepatology and gastroenterology and of microbiology and immunology, $69 million...

Read More Learn More
Single drug injection wards off COVID-19 hospitalizations, in Stanford Medicine-led trial

Single drug injection wards off COVID-19 hospitalizations, in Stanford Medicine-led trial

A single dose of lambda-interferon reduced hospitalization among COVID-19 outpatients in a late-stage study spearheaded by a Stanford Medicine virologist.

Read More Learn More
Antiviral Program for Pandemics

Antiviral Program for Pandemics

The Antiviral Program for Pandemics (APP) aims to develop safe and effective antivirals to combat SARS-CoV-2, the virus that causes COVID-19, as well as to build sustainable platforms for targeted drug discovery and development of a robust pipeline of antivirals against viruses with pandemic potential.

Read More Learn More
Craig Cameron
Craig Cameron PhD UNC SOM

Professor and Chair of Microbiology and Immunology at University of North Carolina at Chapel Hill School of Medicine

AbdulRahimFerhan
Dr. Abdul Rahim Ferhan Nanyang Technological University, Singapore Deputy Director, Translational Research ViRx@Stanford for Vietnam

Dr. Edward Pham receives his MD and Ph.D in Microbiology & Immunology from Stanford University.

His research focus is on novel antiviral therapies for current and emerging viral infections and the relationship between chronic viral infection and cancer including liver cancer through studying how the innate and adaptive immune system are perturbed in chronic viral infection.

He has been recognized by many prestigious awards such as National Research Service Fellowship from NIH for MD/PhD, Gates Millenium Scholar, Howard Hughes Medical Institute, International Achievement Summit Delegate.

EdwardPham
Mark Smith PhD, University of Manchester Head of Medicinal Chemistry of Stanford

Dr. Mark Smith joined Stanford ChEM-H in May 2013 as the Head of the Medicinal Chemistry Knowledge Center. He graduated with a Ph.D. from the laboratory of Prof. Richard Stoodley at the University of Manchester Institute for Science and Technology (UMIST), where his research focused on the application of Lewis acid catalyzed hetero Diels-Alder reactions to the synthesis of novel disaccharide structures. In 2000, Dr.

Smith joined the research laboratory of Prof. David Crich at the University of Illinois at Chicago. Here his research focused on the generation of new reagents for the synthesis of beta-mannosides from thioglycosides. From 2002 to 2013, Dr. Smith worked as a medicinal chemist in Roche’s research facilities both in Palo Alto, CA and then Nutley, NJ, where he specialized in antiviral research.